Tolazamide
Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a682482 |
License data |
|
Pregnancy category | |
Routes of administration | Oral |
ATC code | A10BB05 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | metabolized in the liver to active metabolites |
Biological half-life | 7 hours |
Excretion | Renal (85%) and fecal (7%) |
Identifiers | |
| |
CAS Number | 1156-19-0 |
PubChem (CID) | 5503 |
IUPHAR/BPS | 6847 |
DrugBank | DB00839 |
ChemSpider | 5302 |
UNII | 9LT1BRO48Q |
KEGG | D00379 |
ChEBI | CHEBI:9613 |
ChEMBL | CHEMBL817 |
ECHA InfoCard | 100.013.262 |
Chemical and physical data | |
Formula | C14H21N3O3S |
Molar mass | 311.401 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(verify) |
Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes. It is part of the sulfonylurea family (ATC A10BB).
Synthesis
para-Toluenesulfonamide is converted to its carbamate with ethyl chloroformate in the presence of a base. Heating that intermediate with azepane leads to the displacement of the ethoxy group and the formation of tolazemide:[1]
References
External links
This article is issued from Wikipedia - version of the 8/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.